Adam Feuerstein articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2013/05/21 15:22
2013/05/21 15:22
6h
Why Keryx is Lagging But Acadia is Zooming (Hint:...
Unlike Keryx, Acadia's stock (the orange line) kept pace with the Nasdaq Biotech Index. In April, Acadia zoomed and has since outperformed the broader biotech sector. What happened in April? That's...
FDA Adam Feuerstein TheStreet
MENTIONED
2013/05/21 15:22
2013/05/21 15:22
Latest videos
2013/05/21 15:22
2013/05/21 15:22
Latest from Twitter
2013/05/17 15:22
2013/05/17 15:22
4d
Quick Take: The Next Big Thing in Biotech
NEW YORK (TheStreet) -- TheStreet's senior columnist Adam Feuerstein and Gregg Greenberg talked about the research abstracts ahead of the American Society of Clinical Oncology event later this...
6
RELATED
Bret Kenwell NEW YORK TheStreet David Peltier Rocco Pendola
MENTIONED
2013/05/16 00:22
2013/05/16 00:22
5d
ASCO '13 Preview: Gilead's Big Cancer Debut
Gilead Sciences is already underway with a phase III study of idelalisib in patients with advanced CLL. The drug is also being studied in indolent non-Hodgkins lymphoma. Investors have been even more...
1
RELATED
Adam Feuerstein TheStreet Gilead Sciences Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center
MENTIONED
2013/05/16 00:22
2013/05/16 00:22
5d
ASCO '13 Preview: Roche's Next-Gen Rituxan Steps ...
Sixty-seven percent of GA101-treated patients experience a serious side effect, including 34% reporting significant drops in white blood cell counts known as neutropenia. By comparison, the rate of...
Rituxan Adam Feuerstein FDA TheStreet
MENTIONED
2013/05/13 12:22
2013/05/13 12:22
8d
SEC Is Investigating Spectrum Pharma
Spectrum tucked the disclosure of an SEC subpoena in its most recent 10-Q filed last Thursday. The company made no mention of the investigation in the press release announcing first-quarter financial...
U.S. Securities and Exchange Commission Adam Feuerstein TheStreet
MENTIONED
2013/05/10 11:22
2013/05/10 11:22
11d
Synta, Zogenix, Sarepta, Amarin
Omthera seems like the kind of company which goes public because the more favorable option -- being acquired by a large pharmaceutical company -- wasn't happening. The publication of another study...
Adam Feuerstein Environmental Protection Agency FDA NEW YORK TheStreet
MENTIONED
2013/05/09 12:22
2013/05/09 12:22
12d
Repros Patent Problems Began When Harry Met Joe
... my patent is nothing to worry about, then why has Repros asked the U.S. patent office to re-examine my patent twice and lost both times," Fisch asks. "And why does Repros warn investors in its SEC...
Adam Feuerstein U.S. Securities and Exchange Commission TheStreet
MENTIONED
2013/05/06 17:22
2013/05/06 17:22
15d
Fire Aveo's CEO for Incompetence and Arrogance Ri...
Powerful stuff. What's next for Aveo? Let's hope someone on the company's board steps forward to ensure that someone high up at Aveo is held accountable for last week's disastrous loss of shareholder...
Adam Feuerstein FDA Erbitux TheStreet Boston
MENTIONED
2013/05/01 16:22
2013/05/01 16:22
20d
An Outrageous, Shameless Act by Hemispherx's Boar...
For the record, here are the names and credentials of the independent directors sitting on Hemispherx's board: Richard Piani, principal delegate for Industry to the City of Science and Industry,...
Adam Feuerstein NEWPORT BEACH Paris William Mitchell TheStreet
MENTIONED
2013/04/30 15:22
2013/04/30 15:22
21d
FDA Tells Delcath No Approval Without New Clinica...
NEW YORK (TheStreet) -- Delcath Systems(DCTH) is in serious trouble two days before an FDA advisory panel meets to review its medical device-chemotherapy system known as Melblez. In a scorching...
FDA NEW YORK Adam Feuerstein TheStreet Boston
MENTIONED
2013/04/26 12:22
2013/04/26 12:22
25d
ASCO, Sarepta, Cel-Sci and Hate Mail!
My take: None of these doubts about an accelerated approval are new, and as I've said many times before, this view is consensus and the stock still trades above $30 per share. If you don't day trade,...
1
RELATED
Adam Feuerstein TheStreet FDA Sutent Avastin
MENTIONED
2013/04/24 11:22
2013/04/24 11:22
27d
Vertex CFO Rings Register On $35 Million Insider ...
CAMBRIDGE, Mass. (TheStreet) -- Vertex Pharmaceuticals'(VRTX) Chief Financial Officer Ian Smith sold options and stock last week netting him more than $35 million. Smith rang the cash register on his...
Vertex Pharmaceuticals Ian Smith Smith Adam Feuerstein Cambridge
MENTIONED
2013/04/23 21:22
2013/04/23 21:22
28d
A Big Tax Break, But Not Stellar Sales, Helps Amg...
THOUSAND OAKS, Calif. (TheStreet) -- Amgen(AMGN) posted adjusted earnings for the first quarter that grew 22% and beat Street expectations. However, Amgen's bottom-line beat was driven largely by tax...
Amgen Adam Feuerstein TheStreet
MENTIONED
2013/04/23 15:22
2013/04/23 15:22
28d
Bristol Still Playing Catch-Up To Gilead In Hep C...
AMSTERDAM (TheStreet) -- Hepatitis C drug developers dumped a ton of clinical data on investors this morning as a liver disease meeting gets underway in Amsterdam. An experimental triple combination...
Bristol Adam Feuerstein Bristol-Myers Squibb Amsterdam Gilead Sciences
MENTIONED
2013/04/23 14:22
2013/04/23 14:22
28d
Celsion's Shameless Spin Job
Here I thought Celsion was doing the honorable thing by making no excuses for the failure of its Thermodox liver cancer therapy. Last January, CEO Michael Tardugno told investors, straight up, that...
2013/04/23 12:22
2013/04/23 12:22
28d
Ironwood's Constipation Drug Sales Disappoint
Net sales of Linzess totaled $4.5 million for the quarter ended March 30, well below analyst expectations of sales in the $11-13 million range. Linzess was approved in December, so the first quarter...
2013/04/22 14:22
2013/04/22 14:22
29d
Amarin's Fish Oil Pill Faces Even More Exclusivit...
Generic drug companies don't market their products, but in this case, Amarin would be doing the marketing for them. If you think through this scenario, it helps explain why Amarin was never acquired...
Adam Feuerstein TheStreet
MENTIONED
2013/04/19 13:22
2013/04/19 13:22
m
Worth Repeating: Vertex Is the Next Gilead Scienc...
Vertex cystic fibrosis revenue of $6-7 billion year is equal to what Gilead generates in revenue every year from is antiviral product sales, mostly its dominant HIV drugs. Comparing Vertex to Gilead...
Vertex HIV Adam Feuerstein Atripla Truvada
MENTIONED
Parts of this website powered by Open Calais, a toolkit for rich semantic metadata extraction.

Huh, what is this?
Interceder is a topic search engine aggregating the latest news on any topic into a single window of information. This page has been automatically generated. To contact Interceder click here.

Privacy Statement
Your privacy is important. Interceder does not collect and keep any personal information about visitors to the site. Interceder may use third-party advertising companies to serve ads. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements on this website, other websites, and other forms of media about goods and services of interest to you.